Comparison of Aortobifemoral Bypass and Endovascular Treatment for Chronic Infrarenal Abdominal Aortic Occlusion From the CHAOS (CHronic Abdominal Aortic Occlusion, ASian Multicenter) Registry

医学 血管内治疗 倾向得分匹配 血运重建 外科 腹部外科 腹主动脉 闭塞 主动脉 心脏病学 内科学 心肌梗塞 动脉瘤
作者
Naoki Fujimura,Mitsuyoshi Takahara,Hideaki Obara,Shigeo Ichihashi,R. George,Kimihiro Igari,Hiroshi Banno,Koji Hozawa,Terutoshi Yamaoka,Ch’ng Jack Kian,Jimmy Wei-Hwa Tan,Ki Hyuk Park,Skyi Yin‐Chun Pang,Taku Kato,Osami Kawarada
出处
期刊:Journal of Endovascular Therapy [SAGE]
卷期号:30 (6): 828-837 被引量:8
标识
DOI:10.1177/15266028221098710
摘要

To directly compare the clinical outcomes of aortobifemoral bypass surgery (ABF) and endovascular treatment (EVT) for chronic total occlusion (CTO) of the infrarenal abdominal aorta (IAA).In this retrospective, multicenter study, we used an international database of 436 patients who underwent revascularization for CTO of the IAA between 2007 and 2017 at 30 Asian cardiovascular centers. After excluding 52 patients who underwent axillobifemoral bypass surgery, 384 patients (139 ABFs and 245 EVTs) were included in the analysis. Propensity score-matched analysis was performed to compare clinical results in the periprocedural period and the long-term.Propensity score matching extracted 88 pairs. Procedure time (ABF; 288 [240-345] minutes vs EVT; 159 [100-205] minutes, p<0.001) and length of hospital stay (17 [12-23] days vs 5 [4-13] days, p<0.001) were significantly shorter in the EVT group than in the ABF group, while the proportions of procedural success (98.9% versus 96.6%, p=0.620), complications (9.1% versus 12.3%, p=0.550), and mortality (2.3% versus 3.8%, p=1.000) were not different between the groups. At 1 months, ABI significantly increased more in the ABF group for both in a limb with the lower (0.56 versus 0.50, p=0.018) and the higher (0.49 versus 0.34, p=0.001) baseline ABI, while the change of the Rutherford category was not significantly different between the groups (p=0.590). At 5 years, compared with the EVT group, the ABF group had significantly better primary patency (89.4±4.3% versus 74.8±4.3%, p=0.035) and survival rates (86.9±4.5% versus 66.2±7.5%, p=0.007). However, there was no significant difference between the groups for secondary patency (100.0%±0.0% versus 93.5%±3.9%, p=0.160) and freedom from target lesion revascularization (TLR) (89.3±4.3% vs 77.3±7.3%, p=0.096).Even with recent advancements in EVT, primary patency was still significantly better for ABF in CTO of the IAA. However, there was no difference between the groups in terms of secondary patency and freedom from TLR at 5 years. Furthermore, there was no difference in procedural success, complications, mortality, and improvement in the Rutherford classification during the periprocedural period, with significantly shorter procedure time and hospital stay in the EVT group.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
J_Xu完成签到 ,获得积分10
刚刚
清秀谷南完成签到,获得积分10
刚刚
猪猪hero应助矮小的断秋采纳,获得10
1秒前
Wanfeng应助张俊扬采纳,获得200
2秒前
2秒前
3秒前
石大李克发布了新的文献求助10
3秒前
wanci应助热心幻天采纳,获得10
4秒前
体贴皮卡丘完成签到 ,获得积分10
4秒前
老天师一巴掌完成签到 ,获得积分10
4秒前
6秒前
LewisAcid应助gloval采纳,获得50
6秒前
SCI朝我来完成签到,获得积分10
7秒前
wuxunxun2015发布了新的文献求助10
7秒前
刘欣发布了新的文献求助10
8秒前
酷波er应助BananaL采纳,获得10
8秒前
量子星尘发布了新的文献求助10
8秒前
9秒前
9秒前
瑾瑜匿瑕发布了新的文献求助20
9秒前
eric发布了新的文献求助10
9秒前
9秒前
11秒前
Orange应助popura_YY采纳,获得10
11秒前
12秒前
心肝宝贝甜蜜饯完成签到,获得积分10
12秒前
12秒前
de发布了新的文献求助10
13秒前
不加香菜完成签到 ,获得积分10
13秒前
核桃发布了新的文献求助30
15秒前
laity发布了新的文献求助10
16秒前
eric完成签到,获得积分10
16秒前
诚心宛筠应助无语的夜春采纳,获得10
17秒前
enen发布了新的文献求助10
17秒前
17秒前
热心幻天发布了新的文献求助10
18秒前
归尘发布了新的文献求助10
19秒前
善良的茗茗完成签到,获得积分20
20秒前
22秒前
西瓜西瓜完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Basic And Clinical Science Course 2025-2026 3000
人脑智能与人工智能 1000
花の香りの秘密―遺伝子情報から機能性まで 800
Process Plant Design for Chemical Engineers 400
Principles of Plasma Discharges and Materials Processing, 3rd Edition 400
Signals, Systems, and Signal Processing 400
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5613310
求助须知:如何正确求助?哪些是违规求助? 4698482
关于积分的说明 14898087
捐赠科研通 4735844
什么是DOI,文献DOI怎么找? 2546985
邀请新用户注册赠送积分活动 1510961
关于科研通互助平台的介绍 1473545